Cardiovascular Imaging Research Center (CIRC), Department of Radiology, Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Cardiology Division, New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, New York.
J Am Coll Cardiol. 2020 Feb 11;75(5):467-478. doi: 10.1016/j.jacc.2019.11.049.
There is a need for improved methods for detection and risk stratification of myocarditis associated with immune checkpoint inhibitors (ICIs). Global longitudinal strain (GLS) is a sensitive marker of cardiac toxicity among patients receiving standard chemotherapy. There are no data on the use of GLS in ICI myocarditis.
This study sought to evaluate the role of GLS and assess its association with cardiac events among patients with ICI myocarditis.
This study retrospectively compared echocardiographic GLS by speckle tracking at presentation with ICI myocarditis (cases, n = 101) to that from patients receiving an ICI who did not develop myocarditis (control subjects, n = 92). Where available, GLS was also measured pre-ICI in both groups. Major adverse cardiac events (MACE) were defined as a composite of cardiogenic shock, arrest, complete heart block, and cardiac death.
Cases and control subjects were similar in age, sex, and cancer type. At presentation with myocarditis, 61 cases (60%) had a normal ejection fraction (EF). Pre-ICI, GLS was similar between cases and control subjects (20.3 ± 2.6% vs. 20.6 ± 2.0%; p = 0.60). There was no change in GLS among control subjects on an ICI without myocarditis (pre-ICI vs. on ICI, 20.6 ± 2.0% vs. 20.5 ± 1.9%; p = 0.41); in contrast, among cases, GLS decreased to 14.1 ± 2.8% (p < 0.001). The GLS at presentation with myocarditis was lower among cases presenting with either a reduced (12.3 ± 2.7%) or preserved EF (15.3 ± 2.0%; p < 0.001). Over a median follow-up of 162 days, 51 (51%) experienced MACE. The risk of MACE was higher with a lower GLS among patients with either a reduced or preserved EF. After adjustment for EF, each percent reduction in GLS was associated with a 1.5-fold increase in MACE among patients with a reduced EF (hazard ratio: 1.5; 95% confidence interval: 1.2 to 1.8) and a 4.4-fold increase with a preserved EF (hazard ratio: 4.4; 95% confidence interval: 2.4 to 7.8).
GLS decreases with ICI myocarditis and, compared with control subjects, was lower among cases presenting with either a preserved or reduced EF. Lower GLS was strongly associated with MACE in ICI myocarditis presenting with either a preserved or reduced EF.
需要改进的方法来检测和分层与免疫检查点抑制剂(ICI)相关的心肌炎的风险。整体纵向应变(GLS)是接受标准化疗的患者心脏毒性的敏感标志物。关于 ICI 心肌炎中 GLS 的使用尚无数据。
本研究旨在评估 GLS 的作用,并评估其与 ICI 心肌炎患者心脏事件的相关性。
本研究回顾性比较了 101 例 ICI 心肌炎患者(病例组)和 92 例未发生心肌炎的 ICI 患者(对照组)的斑点追踪超声心动图 GLS。如有可能,两组均在 ICI 前测量 GLS。主要不良心脏事件(MACE)定义为心源性休克、骤停、完全性心脏阻滞和心脏死亡的复合事件。
病例组和对照组在年龄、性别和癌症类型方面相似。在心肌炎发作时,61 例(60%)的射血分数正常。在 ICI 前,病例组和对照组的 GLS 相似(20.3±2.6%比 20.6 ± 2.0%;p=0.60)。在没有心肌炎的情况下接受 ICI 的对照组中,GLS 没有变化(ICI 前与 ICI 时,20.6±2.0%比 20.5±1.9%;p=0.41);相比之下,病例组的 GLS 下降至 14.1±2.8%(p<0.001)。在 MACE 中,心肌炎发作时 GLS 较低的病例,其射血分数无论是降低(12.3±2.7%)还是保留(15.3 ± 2.0%;p<0.001)。在中位随访 162 天期间,51 例(51%)发生 MACE。射血分数降低或保留时,GLS 降低与 MACE 风险升高相关。在调整射血分数后,射血分数降低的患者中 GLS 每降低 1%,MACE 的风险增加 1.5 倍(危险比:1.5;95%置信区间:1.2 至 1.8),射血分数保留的患者中增加 4.4 倍(危险比:4.4;95%置信区间:2.4 至 7.8)。
ICI 心肌炎时 GLS 降低,与对照组相比,射血分数降低或保留时的病例组 GLS 更低。在射血分数降低或保留的 ICI 心肌炎患者中,较低的 GLS 与 MACE 密切相关。